Hunter Associates Investment Management LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,317 shares of the medical equipment provider’s stock after selling 340 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Hologic were worth $1,648,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Quantbot Technologies LP boosted its holdings in Hologic by 97.5% during the 2nd quarter. Quantbot Technologies LP now owns 7,070 shares of the medical equipment provider’s stock valued at $320,000 after acquiring an additional 3,491 shares during the period. California Public Employees Retirement System boosted its holdings in Hologic by 4.0% during the 2nd quarter. California Public Employees Retirement System now owns 584,100 shares of the medical equipment provider’s stock valued at $26,506,000 after acquiring an additional 22,300 shares during the period. ETRADE Capital Management LLC boosted its holdings in Hologic by 19.4% during the 2nd quarter. ETRADE Capital Management LLC now owns 15,178 shares of the medical equipment provider’s stock valued at $689,000 after acquiring an additional 2,467 shares during the period. Vanguard Group Inc. boosted its holdings in Hologic by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after acquiring an additional 1,200,825 shares during the period. Finally, Northern Trust Corp boosted its holdings in Hologic by 2.5% during the 2nd quarter. Northern Trust Corp now owns 3,277,739 shares of the medical equipment provider’s stock valued at $148,743,000 after acquiring an additional 79,697 shares during the period. Institutional investors own 96.38% of the company’s stock.

In related news, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Elaine Ullian sold 8,849 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $45.28, for a total value of $400,682.72. Following the completion of the transaction, the director now owns 23,810 shares in the company, valued at approximately $1,078,116.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,594 shares of company stock worth $1,168,871. Insiders own 0.79% of the company’s stock.

A number of equities analysts recently commented on the company. Jefferies Group LLC restated a “buy” rating and set a $49.00 target price on shares of Hologic in a report on Wednesday, June 28th. Bank of America Corporation restated a “neutral” rating and set a $48.00 target price (up from $44.00) on shares of Hologic in a report on Friday, July 21st. Piper Jaffray Companies restated a “buy” rating and set a $51.00 target price on shares of Hologic in a report on Friday, July 14th. Stifel Nicolaus restated a “buy” rating on shares of Hologic in a report on Friday, July 14th. Finally, BidaskClub cut Hologic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $48.64.

Hologic, Inc. (HOLX) traded up 0.16% during midday trading on Friday, reaching $37.59. The company’s stock had a trading volume of 513,405 shares. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80. The company has a 50 day moving average of $38.51 and a 200-day moving average of $42.54. The company has a market capitalization of $10.54 billion, a P/E ratio of 14.00 and a beta of 0.92.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. During the same quarter in the previous year, the firm posted $0.51 earnings per share. The company’s revenue was up 12.4% compared to the same quarter last year. Equities research analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.

WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/22/hologic-inc-holx-shares-sold-by-hunter-associates-investment-management-llc.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.